AbbVie to acquire Apogee for $10.9bn
Listed US-based global biopharmaceutical company AbbVie has agreed to acquire clinical stage biotechnology firm Apogee Therapeutics in an all cash transaction valued at approximately $10.9bn. This purchase price represents a premium of approximately 49 per cent to the closing price of Apogee shares on June 18, 2026. The transaction, which has been unanimously approved by the boards of both companies,…